Clik here to view.
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full...
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19...
View ArticleClik here to view.
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised...
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether...
View ArticleClik here to view.
A Predictive Diagnostic Model for IgA Vasculitis Based on a Metabolomic Approach
Background/Purpose: IgA vasculitis is a rare systemic disease that is life-threatening mainly due to digestive or renal involvement. To date, there is no reliable diagnostic marker. The objective was...
View ArticleClik here to view.
Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in...
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a life- or organ-threatening condition in which patients experience severe inflammation of small blood...
View ArticleClik here to view.
Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX)...
Background/Purpose: Disease control remains an unmet need in SLE. The rationale for sequential BEL and RTX therapy in SLE was previously published.1 This study evaluated the efficacy, safety, and...
View ArticleClik here to view.
Neither Add-on nor Withdrawal of Methotrexate Impacts Efficacy of IL12/23...
Background/Purpose: Methotrexate (MTX) is often used as first-line DMARD-therapy in active psoriatic arthritis (PsA). Randomized clinical trials usually require treatment failure or intolerance of...
View ArticleClik here to view.
Cardiovascular Risk of Hydroxychloroquine in the Treatment of Rheumatoid...
Background/Purpose: Hydroxychloroquine (HCQ) is a commonly used 1st-line disease-modifying antirheumatic drug (DMARD) for patients with rheumatoid arthritis (RA) in the U.S., while methotrexate (MTX)...
View ArticleClik here to view.
A Randomized, Double-Blinded, Placebo-Controlled, Phase 2 Study of Safety,...
Background/Purpose: Rheumatoid arthritis-associated interstitial lung disease (RA-ILD) is a prevalent and morbid condition leading to premature death in 10% of those affected. The TRAIL1 trial was a...
View ArticleClik here to view.
A Prediction Model to Distinguish Patients with Multisystem Inflammatory...
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a rare consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C shares features with common...
View ArticleClik here to view.
Association of Limited Health Literacy with Clinical and Patient-Reported...
Background/Purpose: Health literacy (HL) is an important social determinant of health defined as the ability to understand and use health information. Limited HL is associated with worse clinical...
View ArticleClik here to view.
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in...
Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on...
View ArticleClik here to view.
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment...
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy...
View ArticleCOVID-19 Vaccine in Immunosuppressed Adults with Autoimmune Diseases
Background/Purpose: Immunocompromised conditions and/or a history of autoimmune disease were exclusion criteria of the initial SARS-CoV-2 vaccines clinical trials. We assessed the safety and...
View ArticleAdditional Heterologous versus Homologous Booster Vaccination in...
Background/Purpose: Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2)-induced coronavirus disease 2019 (COVID-19) has led to exponentially rising mortality, particularly in immunosuppressed...
View ArticleClik here to view.
Immunogenicity of mRNA COVID-19 Vaccines at 4 and 12 Weeks Post Full...
Background/Purpose: Emerging evidence indicates that immunosuppressive therapies may result in reduced immunogenicity –and presumably reduced efficacy- following vaccination with mRNA COVID-19...
View ArticleClik here to view.
Breakthrough COVID-19 Infections Post-vaccination Among Immunocompromised...
Background/Purpose: National U.S. data on breakthrough COVID-19 infection in people with autoimmune or inflammatory rheumatic diseases (AIRD) are limited. Our objective was to assess whether...
View ArticleClik here to view.
A Prediction Model to Distinguish Patients with Multisystem Inflammatory...
Background/Purpose: Multisystem inflammatory syndrome in children (MIS-C) is a rare consequence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). MIS-C shares features with common...
View ArticleClik here to view.
Association of Limited Health Literacy with Clinical and Patient-Reported...
Background/Purpose: Health literacy (HL) is an important social determinant of health defined as the ability to understand and use health information. Limited HL is associated with worse clinical...
View ArticleClik here to view.
Depletion of KLRG1+ T Cells in a First-in-human Clinical Trial of ABC008 in...
Background/Purpose: Inclusion body myositis (IBM), a relentlessly progressive autoimmune skeletal muscle disease, has no effective available pharmacological therapy. A prominent feature of IBM on...
View ArticleClik here to view.
Comparative Safety of Gout “Treat-to-target” and “Usual Care” Treatment...
Background/Purpose: Rheumatology societies recommend serum-urate (SU)-driven treat-to-target (TTT) strategies for the management of gout. However, cardiovascular (CV) safety of urate-lowering therapy...
View Article